PT-141, prescribed — not just shipped.

PT-141 is a small synthetic peptide, an analog of alpha-melanocyte-stimulating hormone, the signaling molecule the body uses at the melanocortin receptors. It arrived at this category sideways. The molecule came out of research on a tanning compound, and the sexual-response signal investigators kept noticing in that work became the reason it was developed on its own.

The receptor that matters most in the published research is MC4R, which is expressed in the brain, including in the hypothalamus. That is a different address from where the familiar oral medications act, and it is why PT-141 sits in our mood and libido category rather than anywhere vascular.

Bremelanotide is not FDA-approved in compounded form; the one FDA-approved bremelanotide product is indicated for one narrow use: acquired, generalized hypoactive sexual desire disorder in premenopausal women. That is the extent of the approval. The compounded PT-141 prescribed through Promise is not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.

The trial literature behind that approval is the strongest human data the compound has, and it is worth reading plainly. The reported effects were modest. Nausea was the most commonly reported adverse event, with flushing and headache close behind, and transient changes in blood pressure and heart rate have been described. Repeated dosing has been associated with skin darkening in some people, an expected consequence of acting on melanocortin receptors.

None of that is a reason to be squeamish about the compound. It is a reason it goes through a prescriber.

If you are prescribed, your medication is compounded and dispensed by a licensed U.S. pharmacy, and shipped in discreet, temperature-safe packaging. Dosing and timing come from your provider's protocol rather than from a chart found online; the distance between a reasonable dose and an unpleasant one is one of the reasons this is a prescription at all.

After that it is follow-up. Your care team checks in, and anything that needs adjusting gets adjusted with a clinician involved. If you want to understand the other compound studied in this category, kisspeptin approaches the same territory from upstream, through the hormone axis rather than through central melanocortin signaling.